Fig. 2
From: Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
MSxPRM performance of hybrid-PRM/DIA on 185 TAA tumor-associated antigen peptides of 64 proteins. A Dilution series of the light TAA panel (approx. 0.01–100 fmol) in the heavy TAA reference (approx. 100 fmol, constant), which was used to trigger MSxPRM, and a HeLa digest as background matrix. B Number of identified protein groups in hybrid-PRM/DIA MSxPRM mode, DIA, and PRM for the different dilutions. Samples were measured as triplicates. C Hybrid-PRM/DIA MSxPRM and DIA measurements of the tyrosine-protein kinase Lck peptide DFDQNQGEVVK for 0.01 and 0.1 fmol. Shown are the intensities of the heavy and light transition peaks over three technical replicates